Compound Targets Previously “Undruggable” STAT3 To Combat Cancer
Complete the form below to unlock access to ALL audio articles.
For decades, a transcription factor known as STAT3 has been a major therapeutic target in the treatment of cancer. But STAT3 has largely been considered "undruggable" due to the difficulty of developing compounds to effectively inhibit its activity.
Researchers at the University of Michigan Rogel Cancer Center have taken a promising new approach to targeting STAT3 -- developing a small-molecule compound that harnesses the power of a natural cellular "cleanup" system to get rid of it entirely, rather than traditional methods that have tried to block its action.
The U-M compound was able to achieve a long-lasting and nearly complete elimination of tumors in mouse models of leukemia and lymphoma, the authors report in Cancer Cell.
In a mouse model of leukemia, the degrader eliminated all of the tumors, with the mice remaining tumor free for 60 days. In two mouse models of lymphoma, the drug eliminated all of the tumors for more than 100 days, when the experiments were ended. The compound was well-tolerated by the mice, the researchers note.
"STAT3 plays a major role in almost every aspect of human cancer -- in cancer initiation, progression, metastasis and immune evasion," says study senior author Shaomeng Wang, Ph.D., the Warner-Lambert / Parke-Davis professor and a professor of internal medicine and pharmacology at the U-M Medical School, and a professor of medicinal chemistry at the U-M College of Pharmacy. "It also has been implicated in autoimmune and inflammatory diseases. So, there's a lot of therapeutic potential if one can target STAT3 successfully."
Applying a technology called proteolysis-targeting chimeras (PROTAC), the investigators designed the compound to specifically tag the STAT3 protein for recycling by the body's own cleanup systems. This eliminates the STAT3 protein from cells and tissues and blocks its activity entirely, while leaving the function of related proteins intact.
This new approach circumvents problems seen in drugs aimed at merely inhibiting STAT3's activity, including the accidental targeting of other proteins in the seven-member STAT family, which mediate many aspects of cell growth, differentiation and death, says Wang.
The study's co-first authors are Longchuan Bai, Ph.D. and Haibin Zhou, Ph.D., two research scientists in Wang's lab, Renqi Xu, Ph.D., a postdoctoral fellow in Wang's lab, and Yunjun Zhao Ph.D., a former postdoctoral fellow in Wang's lab and currently a professor in Shanghai, China.
The research team, which included collaborators at the U-M Life Sciences Institute's Center for Structural Biology and the College of Pharmacy's Pharmacokinetics and Mass Spectrometry Core, has since further optimized the compound described in the study into a clinical development candidate.
"In the clinical setting, we hope to be able to achieve a dosing schedule that is convenient for cancer patients, perhaps requiring administration of the drug as little as once a week based upon our study," Wang says.
The group is collaborating with Oncopia Therapeutics, a U-M start-up company, to complete studies required for filing an investigational new drug application with the Federal Food and Drug Administration, which is required to initiate human clinical trials.
Reference: Bai, et al. (2019) A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell DOI: https://doi.org/10.1016/j.ccell.2019.10.002
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.